Dr. Lal PathLabs Limited LALPATHLAB NIFTY_SMALLNSEPHARMA
Healthcare · Diagnostics & Research · India
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India.
READ MORE ›₹1,607.40
+14.62% 1Y
Market & Price
Market Cap
₹26,840.01 Cr
Current Price
₹1,607.40
High / Low (52W)
₹1,728.53 / ₹1,307.60
Beta
0.11
Valuation
Stock P/E
50.75
Industry PE
37.60
Forward P/E
39.02
PEG Ratio
-
Book Value
₹143.09
Price to Book
11.23
P/S
9.71
EV/EBITDA
32.91
Dividend Yield
0.87%
Profitability & Returns
ROCE
27.96%
ROE
21.48%
ROA
13.23%
Profit Margin
18.27%
Op Margin
20.24%
EPS (Latest Qtr)
₹5.41
EPS (TTM)
₹31.67
Balance Sheet & Liquidity
Debt/Equity
0.08
Quick Ratio
3.20
Current Ratio
3.48
Debt
₹199.00 Cr
Total Assets
₹2,716.79 Cr
Current Assets
₹1,363.51 Cr
Working Capital
₹961.16 Cr
Ownership
Promoter Holding
54.90%
Chg in Prom Hold
-
FII / Inst Holding
32.16%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
₹25,751.35 Cr
Total Revenue (TTM)
₹2,762.90 Cr
EBITDA
₹782.50 Cr
Free Cash Flow
₹400.37 Cr
Operating Cash Flow
₹635.70 Cr
Shares Outstanding
₹16.70 Cr
Gross Margin
62.43%
Payout Ratio
39.52%
Growth (CAGR)
Revenue 5Y
5.64%
Profit 5Y
12.21%
Revenue (YoY)
16.60%
Earnings (YoY)
-15.40%
PROS
- Strong return on equity of 21.5%.
- Healthy ROCE of 28.0%.
- Profit CAGR of 12.2% over 5 years.
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 50.8.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LALPATHLAB Dr. Lal PathLabs Limited NIFTY_SMALLNSEPHARMA | 1,607.40 | 50.75 | ₹26,840.01 Cr | 0.87% | 27.96% | 21.48% | 5.64% | 12.21% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,799.20 | 37.59 | ₹4.32 L Cr | 0.92% | 17.94% | 14.72% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 6,667.00 | 68.97 | ₹1.77 L Cr | 0.45% | 18.96% | 16.19% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,410.80 | 68.96 | ₹1.49 L Cr | 0.86% | 9.06% | 16.98% | 13.27% | 20.21% |
| 5 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,401.00 | 29.16 | ₹1.13 L Cr | 0.93% | 14.88% | 11.74% | 7.23% | 11.45% |
| 6 | DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA | 1,303.50 | 25.90 | ₹1.09 L Cr | 0.61% | 14.00% | 11.83% | 10.96% | -2.35% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,077.70 | 21.51 | ₹1.08 L Cr | 0.09% | 19.24% | 18.32% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,267.70 | 19.49 | ₹1.04 L Cr | 0.53% | 28.42% | 26.91% | 19.10% | 131.46% |
| 9 | MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA | 2,375.60 | 51.29 | ₹98,090.71 Cr | 0.08% | 13.78% | 12.45% | 17.73% | 14.28% |
Ad space
Quarterly Results
Figures in INR.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 660.20 Cr | 596.70 Cr | 602.42 Cr | 669.80 Cr | - | 659.80 Cr |
| Cost of Revenue | 221.00 Cr | 203.70 Cr | 195.32 Cr | 221.10 Cr | - | 224.50 Cr |
| Gross Profit | 439.20 Cr | 393.00 Cr | 407.10 Cr | 448.70 Cr | - | 435.30 Cr |
| Operating Expenses | 272.00 Cr | 274.50 Cr | 267.65 Cr | 291.00 Cr | - | 298.10 Cr |
| Operating Income | 167.20 Cr | 118.50 Cr | 139.44 Cr | 157.70 Cr | - | 137.20 Cr |
| EBITDA | 224.40 Cr | 179.10 Cr | 194.93 Cr | 220.40 Cr | - | 173.60 Cr |
| Interest Expense | 6.00 Cr | 5.30 Cr | 5.00 Cr | 4.70 Cr | - | 7.20 Cr |
| Pretax Income | 183.10 Cr | 138.30 Cr | 153.50 Cr | 181.10 Cr | - | 124.30 Cr |
| Tax Provision | 52.30 Cr | 40.20 Cr | -2.05 Cr | 47.10 Cr | - | 32.90 Cr |
| Net Income | 129.20 Cr | 96.70 Cr | 154.84 Cr | 132.40 Cr | - | 90.50 Cr |
| Diluted EPS | 7.74 | 5.79 | - | 7.92 | 9.01 | 5.41 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Revenue | 2,087.40 Cr | 2,016.64 Cr | 2,226.50 Cr | 2,461.22 Cr |
| Cost of Revenue | 502.30 Cr | 729.19 Cr | 764.43 Cr | 823.12 Cr |
| Gross Profit | 1,585.10 Cr | 1,287.46 Cr | 1,462.07 Cr | 1,638.10 Cr |
| Operating Expenses | 848.00 Cr | 935.99 Cr | 995.20 Cr | 1,077.65 Cr |
| Operating Income | 737.10 Cr | 351.46 Cr | 466.87 Cr | 560.44 Cr |
| EBITDA | 613.20 Cr | 531.55 Cr | 678.41 Cr | 789.03 Cr |
| Interest Expense | 30.20 Cr | 37.53 Cr | 29.36 Cr | 22.30 Cr |
| Pretax Income | 474.90 Cr | 343.83 Cr | 505.45 Cr | 624.80 Cr |
| Tax Provision | 124.60 Cr | 102.75 Cr | 143.16 Cr | 132.55 Cr |
| Net Income | 344.80 Cr | 238.85 Cr | 357.74 Cr | 487.14 Cr |
| Diluted EPS | 20.79 | 14.37 | 21.49 | 29.20 |
Compounded Sales Growth
| 5 Years: | 5.64% |
| 1 Year: | 16.60% |
Compounded Profit Growth
| 5 Years: | 12.21% |
| 1 Year: | -15.40% |
Stock Price Performance
| 1 Year: | +14.62% |
| 6 Months: | +3.26% |
| 3 Months: | +15.14% |
| 1 Month: | +14.99% |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Total Assets | 2,353.22 Cr | 2,385.56 Cr | 2,455.96 Cr | 2,716.79 Cr |
| Current Assets | 875.15 Cr | 973.09 Cr | 1,126.70 Cr | 1,363.51 Cr |
| Cash & Equivalents | 378.19 Cr | 263.73 Cr | 360.93 Cr | 292.63 Cr |
| Inventory | 52.54 Cr | 33.81 Cr | 37.31 Cr | 36.13 Cr |
| Receivables | 85.39 Cr | 70.82 Cr | 77.40 Cr | 88.12 Cr |
| Total Liabilities | 809.68 Cr | 686.02 Cr | 570.60 Cr | 510.31 Cr |
| Current Liabilities | 499.99 Cr | 469.75 Cr | 463.58 Cr | 402.35 Cr |
| Long Term Debt | 166.67 Cr | 83.33 Cr | 0 | - |
| Total Debt | 532.43 Cr | 419.50 Cr | 246.93 Cr | 157.43 Cr |
| Total Equity | 1,508.08 Cr | 1,666.30 Cr | 1,849.28 Cr | 2,172.72 Cr |
| Shares Outstanding | 16.67 Cr | 16.67 Cr | 16.70 Cr | 16.72 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Operating Cash Flow | 446.70 Cr | 456.03 Cr | 535.33 Cr | 568.88 Cr |
| Investing Cash Flow | -449.20 Cr | -287.31 Cr | -24.27 Cr | -303.16 Cr |
| Financing Cash Flow | 136.40 Cr | -283.18 Cr | -413.86 Cr | -334.03 Cr |
| Capital Expenditure | -476.10 Cr | -44.57 Cr | -57.43 Cr | -53.87 Cr |
| Free Cash Flow | -29.40 Cr | 411.46 Cr | 477.90 Cr | 515.01 Cr |
| Net Change in Cash | 133.90 Cr | -114.46 Cr | 97.20 Cr | -68.31 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Gross Margin % | 75.9% | 63.8% | 65.7% | 66.6% |
| Operating Margin % | 35.3% | 17.4% | 21.0% | 22.8% |
| Net Margin % | 16.5% | 11.8% | 16.1% | 19.8% |
| ROE % | 22.9% | 14.3% | 19.3% | 22.4% |
| ROCE % | 39.8% | 18.3% | 23.4% | 24.2% |
Shareholding Pattern
Insiders
54.90%
Institutions
32.16%
Public Float
71.32%
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LALPATHLAB
No recent headlines available.